| Literature DB >> 25276058 |
Abstract
Trypanosoma cruzi is the causative agent of Chagas disease. Approximately 8 million people are thought to be affected worldwide. Several players in host lipid metabolism have been implicated in T. cruzi-host interactions in recent research, including macrophages, adipocytes, low density lipoprotein (LDL), low density lipoprotein receptor (LDLR), and high density lipoprotein (HDL). All of these factors are required to maintain host lipid homeostasis and are intricately connected via several metabolic pathways. We reviewed the interaction of T. cruzi with each of the relevant host components, in order to further understand the roles of host lipid metabolism in T. cruzi infection. This review sheds light on the potential impact of T. cruzi infection on the status of host lipid homeostasis.Entities:
Mesh:
Year: 2014 PMID: 25276058 PMCID: PMC4168237 DOI: 10.1155/2014/902038
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Trypanosoma cruzi interacting with various components of host lipid metabolism. (a) T. cruzi infects macrophage and activates TLR-2 signaling which causes the increased lipid bodies (LB) number and altered LB morphology. This effect is further enhanced by macrophage uptake of apoptotic cells. Increased LB number causes increased eicosanoid production, which leads to upregulation of TGF-β and increased cell susceptibility to T. cruzi infection. (b) T. cruzi uses adipocytes as a reservoir for chronic infection. T. cruzi infection causes adipocytes to display an inflammatory phenotype, upregulating cytokines such as IL-1β, IFN-γ, TNF-α, CCL2, CXCL10, and CCL5. TLR-2 and 9, which are essential to T. cruzi infection, are also upregulated. The infection also causes downregulation of adiponectin secretion via PPAR-γ expression. (c) Host LDL inhibits T. cruzi trans-sialidase and increases T. cruzi infection in vitro. LDL can be taken up by the liver and extrahepatic cells by LDLR. It is unknown whether LDL-LDLR interaction plays a role in T. cruzi infection. (d) T. cruzi enters host cell via LDLR. LDL-R activation leads to lysosomal recruitment to parasitophorous vacuole and parasite internalization. (e) HDL inhibits T. cruzi trans-sialidase activity and increases T. cruzi infection in vitro. HDL is uptaken by host cells via receptor mediated interaction with SR-BI. Whether this interaction can be utilized by T. cruzi cell entry process is not known. (f) Apo A-I in the HDL complex is cleaved by the major cysteine protease of T. cruzi, cruzipain. Cruzipain and trans-sialidase are similarly expressed and located during different life stages of T. cruzi. It is possible that HDL is bound to the surface of T. cruzi trypomastigotes by trans-sialidase and is cleaved by cruzipain in the acidic environment in the parasitophorous vacuole. Host cholesterol transport by VLDL, LDL, and HDL is indicated in red arrows. Host VLDL and lipid-poor nascent HDL particles are produced in the liver. By effluxing cholesterol, host VLDL transforms to become LDL and nascent HDL becomes mature HDL. LDL particles can be oxidized and uptaken by macrophage. Lipid-laden macrophages are termed foam cells and are major contributors in host atherosclerosis development. HDL effluxes cholesterol from peripheral tissue via the action of ABCA1 or ABCG1 and returns cholesterol to hepatic tissues for storage or excretion.
Figure 2Possible mechanisms of T. cruzi cruzipain cleaving Apo A-I in HDL. T. cruzi cruzipain is expressed in the parasitic surface as well as in the lysosomal-like structure/reservosome. Both cruzipain fractions are required to produce the full Apo A-I truncation profile seen in T. cruzi infected human patients. This implies that Apo A-I within the HDL complex may be (a) truncated during the infection process on the parasitic surface and also (b) endocytosed by T. cruzi and processed in the reservosome for possible lipid utilization.